These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 22999130)

  • 21. Application of Constrained Optimization Methods in Health Services Research: Report 2 of the ISPOR Optimization Methods Emerging Good Practices Task Force.
    Crown W; Buyukkaramikli N; Sir MY; Thokala P; Morton A; Marshall DA; Tosh JC; Ijzerman MJ; Padula WV; Pasupathy KS
    Value Health; 2018 Sep; 21(9):1019-1028. PubMed ID: 30224103
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Questionnaire to assess relevance and credibility of modeling studies for informing health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report.
    Jaime Caro J; Eddy DM; Kan H; Kaltz C; Patel B; Eldessouki R; Briggs AH;
    Value Health; 2014 Mar; 17(2):174-82. PubMed ID: 24636375
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Applying dynamic simulation modeling methods in health care delivery research-the SIMULATE checklist: report of the ISPOR simulation modeling emerging good practices task force.
    Marshall DA; Burgos-Liz L; IJzerman MJ; Osgood ND; Padula WV; Higashi MK; Wong PK; Pasupathy KS; Crown W
    Value Health; 2015 Jan; 18(1):5-16. PubMed ID: 25595229
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part III.
    Johnson ML; Crown W; Martin BC; Dormuth CR; Siebert U
    Value Health; 2009; 12(8):1062-73. PubMed ID: 19793071
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making.
    Berger ML; Sox H; Willke RJ; Brixner DL; Eichler HG; Goettsch W; Madigan D; Makady A; Schneeweiss S; Tarricone R; Wang SV; Watkins J; Mullins CD
    Value Health; 2017 Sep; 20(8):1003-1008. PubMed ID: 28964430
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improving model validation in health technology assessment: comments on guidelines of the ISPOR-SMDM modeling good research practices task force.
    Vemer P; van Voom GA; Ramos IC; Krabbe PF; Al MJ; Feenstra TL
    Value Health; 2013; 16(6):1106-7. PubMed ID: 24041364
    [No Abstract]   [Full Text] [Related]  

  • 27. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report.
    Ramsey S; Willke R; Briggs A; Brown R; Buxton M; Chawla A; Cook J; Glick H; Liljas B; Petitti D; Reed S
    Value Health; 2005; 8(5):521-33. PubMed ID: 16176491
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6.
    Briggs AH; Weinstein MC; Fenwick EA; Karnon J; Sculpher MJ; Paltiel AD;
    Med Decis Making; 2012; 32(5):722-32. PubMed ID: 22990087
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative effectiveness research: guidelines for good practices are just the beginning.
    Johnson ML; Chitnis AS
    Expert Rev Pharmacoecon Outcomes Res; 2011 Feb; 11(1):51-7. PubMed ID: 21351858
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systematic assessment of decision-analytic models for chronic myeloid leukemia.
    Rochau U; Schwarzer R; Jahn B; Sroczynski G; Kluibenschaedl M; Wolf D; Radich J; Brixner D; Gastl G; Siebert U
    Appl Health Econ Health Policy; 2014 Apr; 12(2):103-15. PubMed ID: 24385259
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part I.
    Berger ML; Mamdani M; Atkins D; Johnson ML
    Value Health; 2009; 12(8):1044-52. PubMed ID: 19793072
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiple Criteria Decision Analysis for Health Care Decision Making--An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force.
    Thokala P; Devlin N; Marsh K; Baltussen R; Boysen M; Kalo Z; Longrenn T; Mussen F; Peacock S; Watkins J; Ijzerman M
    Value Health; 2016 Jan; 19(1):1-13. PubMed ID: 26797229
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Criteria and Process for Initiating and Developing an ISPOR Good Practices Task Force Report.
    Malone DC; Ramsey SD; Patrick DL; Johnson FR; Mullins CD; Roberts MS; Willke RJ; Marshall DA
    Value Health; 2020 Apr; 23(4):409-415. PubMed ID: 32327155
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modeling the value for money of changing clinical practice change: a stochastic application in diabetes care.
    Hoomans T; Abrams KR; Ament AJ; Evers SM; Severens JL
    Med Care; 2009 Oct; 47(10):1053-61. PubMed ID: 19648827
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1.
    Jansen JP; Fleurence R; Devine B; Itzler R; Barrett A; Hawkins N; Lee K; Boersma C; Annemans L; Cappelleri JC
    Value Health; 2011 Jun; 14(4):417-28. PubMed ID: 21669366
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Using whole disease modeling to inform resource allocation decisions: economic evaluation of a clinical guideline for colorectal cancer using a single model.
    Tappenden P; Chilcott J; Brennan A; Squires H; Glynne-Jones R; Tappenden J
    Value Health; 2013 Jun; 16(4):542-53. PubMed ID: 23796288
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Family pediatrics: report of the Task Force on the Family.
    Schor EL;
    Pediatrics; 2003 Jun; 111(6 Pt 2):1541-71. PubMed ID: 12777595
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dynamic medication adherence modeling in primary prevention of cardiovascular disease: a Markov microsimulation methods application.
    Slejko JF; Sullivan PW; Anderson HD; Ho PM; Nair KV; Campbell JD
    Value Health; 2014 Sep; 17(6):725-31. PubMed ID: 25236996
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Health economic evaluations using decision analytic modeling. Principles and practices--utilization of a checklist to their development and appraisal.
    Soto J
    Int J Technol Assess Health Care; 2002; 18(1):94-111. PubMed ID: 11987445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.